• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Translational Development Acquisition Corp.

    5/28/26 5:21:02 PM ET
    $TDAC
    Get the next $TDAC alert in real time by email
    DEFA14A 1 tm2613344d4_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A

    PROXY STATEMENT PURSUANT TO SECTION 14(A)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Filed by the Registrant x Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement
       
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨ Definitive Proxy Statement
       
    x  Definitive Additional Materials
       
    ¨ Soliciting Material under §240.14a-12

     

    TRANSLATIONAL DEVELOPMENT ACQUISITION CORP.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x No fee required.
       
    ¨  Fee paid previously with preliminary materials.
       
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

     

     

     

     

     

    2026 Proposal No. 3 — Adjournment Proposal — A proposal, by ordinary resolution to adjourn the Extraordinary General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Extraordinary General Meeting, there are not sufficient votes to approve the Extension Amendment Proposal, the Trust Agreement Amendment Proposal, or to provide additional time to effectuate the Extension Amendment and Extension (the “Adjournment Proposal”).Proposal No. 1 — Extension Amendment Proposal — A proposal, by special resolution, to amend Translational Development Acquisition Corp. (the “Company”)’s Amended and Restated Memorandum and Articles of Association as adopted by special resolution dated December 20, 2024, (the “Existing Charter”) by adopting an amendment to the Existing Charter in the form set forth in Annex A to the Proxy Statement (the “Extension Amendment”) which reflects the extension of the date by which the Company must consummate a business combination (the “Combination Period”) up to twelve (12) times from June 24, 2026 (the “Deadline Date”) to June 24, 2027, each by an additional one (1) month (each an “Extension”) for a total of twelve (12) months after the Deadline Date, assuming a Business Combination has not occurred. The end date of each Extension shall be referred to herein as the “Extended Date.” We refer to this proposal as the “Extension Amendment Proposal”; Proposal No. 2 — Trust Agreement Amendment Proposal — A proposal to further amend Translational Development’s investment management trust agreement, dated as of December 23, 2024, (the “Trust Agreement”), by and between the Company and Continental Stock Transfer & Trust Company (the “Trustee”), to allow the Company to extend the Deadline Date up to twelve (12) times for an additional one (1) month each time from the Deadline Date to June 24, 2027 (the “Trust Agreement Amendment”) by providing five days’ advance notice to the Trustee prior to the applicable Deadline Date and depositing into the trust account (the “Trust Account”) the lessor of $200,000 or $0.03 per outstanding public share for each one-month extension two (2) days prior to such Extension (the “Extension Payment”) until June 24, 2027 (assuming a Business Combination has not occurred) in exchange for a non-interest bearing, unsecured promissory note payable upon the consummation of a Business Combination (the “Trust Agreement Amendment Proposal”);TRANSLATIONAL DEVELOPMENT ACQUISITION CORP. FOLD HERE • DO NOT SEPARATE • INSERT IN ENVELOPE PROVIDED Signature Signature, if held jointly Date 2026. Note: Signature should agree with name printed hereon. If shares are held in the name of more than one person, EACH joint owner should sign. Executors, administrators, trustees, guardians, and attorneys should indicate the capacity in which they sign. Attorneys should submit powers of attorney. Please mark your votes like this X206687 Translational Development Acquisition Corp Proxy Card Rev 2 - Front CONTROL NUMBER PROXY THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” PROPOSALS 1, 2 AND 3. PLEASE DO NOT RETURN THE PROXY CARD IF YOU ARE VOTING ELECTRONICALLY. INTERNET – www.cstproxyvote.com Use the Internet to vote your proxy. Have your proxy card available when you access the above website. Follow the prompts to vote your shares. Vote at the Meeting – If you plan to attend the virtual online extraordinary general meeting, you will need your 12 digit control number to vote electronically at the extraordinary general meeting. To attend the extraordinary general meeting, visit: https://www.cstproxy.com/tdac/2026 MAIL – Mark, sign and date your proxy card and return it in the postage-paid envelope provided. Your Internet vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed and returned your proxy card. Votes submitted electronically over the Internet must be received by 11:59 p.m., Eastern Time, on June 16, 2026.YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. IMMEDIATE - 24 Hours a Day, 7 Days a Week or by MailVote by Internet - Q U I C K E A S Y FOR AGAINST ABSTAIN FOR AGAINST ABSTAIN FOR AGAINST ABSTAIN

    2026 FOLD HERE • DO NOT SEPARATE • INSERT IN ENVELOPE PROVIDED PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS TRANSLATIONAL DEVELOPMENT ACQUISITION CORP. The undersigned, revoking any previous proxies relating to these shares, hereby acknowledges receipt of the Notice and Proxy Statement, dated May 27, 2026, in connection with the extraordinary general meeting of shareholders (the “Shareholder Meeting”) of Translational Development Acquisition Corp. the “Company” to be held at 10:00 a.m. Eastern Time on June 17, 2026, via a virtual meeting at https://www.cstproxy.com/tdac/2026, and hereby appoints Michael B. Hoffman, with full power to act alone, the attorney and proxy of the undersigned, with power of substitution, to vote all stock of the Company registered in the name provided, which the undersigned is entitled to vote at the Shareholder Meeting, and at any adjournments thereof, with all the powers the undersigned would have if personally present. Without limiting the general authorization hereby given, said proxy is instructed to vote or act as follows on the proposals set forth in the accompanying proxy statement/prospectus. THIS PROXY, WHEN EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED HEREIN. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED “FOR” PROPOSALS 1, 2 AND 3. PLEASE SIGN, DATE AND RETURN THE PROXY IN THE ENVELOPE ENCLOSED TO CONTINENTAL STOCK TRANSFER & TRUST COMPANY. THIS PROXY WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED SHAREHOLDER. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED “FOR” PROPOSALS 1, 2 AND 3 AND WILL GRANT DISCRETIONARY AUTHORITY TO VOTE UPON SUCH OTHER MATTERS AS MAY PROPERLY COME BEFORE THE MEETING OR ANY ADJOURNMENTS THEREOF. THIS PROXY WILL REVOKE ALL PRIOR PROXIES SIGNED BY YOU.(Continued and to be marked, dated and signed on the other side) Important Notice Regarding the Internet Availability of Proxy Materials for the Extraordinary General Meeting of Shareholders of Translational Development Acquisition Corp. to be held on June 17, 2026 To view the 2026 Proxy Statement and to Attend the Extraordinary General Meeting, please go to: https://www.cstproxy.com/tdac/2026206687 Translational Development Acquisition Corp Proxy Card Rev2 - Back

     

    Get the next $TDAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TDAC

    DatePrice TargetRatingAnalyst
    9/21/2021$16.00Outperform
    Northland Capital Markets
    More analyst ratings

    $TDAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chairman and CEO Hoffman Michael B

    4 - Translational Development Acquisition Corp. (0001926599) (Issuer)

    5/29/26 4:05:16 PM ET
    $TDAC

    SEC Form 3 filed by new insider Jarratt Christopher Kenneth

    3 - Translational Development Acquisition Corp. (0001926599) (Issuer)

    1/6/25 4:05:09 PM ET
    $TDAC

    SEC Form 3 filed by new insider Keith Curtis T

    3 - Translational Development Acquisition Corp. (0001926599) (Issuer)

    12/20/24 6:59:32 PM ET
    $TDAC

    $TDAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TDAC Announces ProLogium's Filing of F-4 As Continuing Momentum Towards Merger

    NEW YORK, July 6, 2026 /PRNewswire/ -- Translational Development Acquisition Company (NYSE:TDAC) ( "TDAC") announced that ProLogium has filed their initial F-4 with the SEC driving the companies forward towards a successful execution of the de-SPAC transaction. This filing gives the SEC and investors at large a fuller view into the history of ProLogium and further supporting information into the merger transaction that was announced on May 27, 2026. Michael Hoffman, Chairman and CEO of TDAC, commented, "We continue to be tremendously excited to work with the ProLogium team on this transaction. We believe that this F-4 filing with the SEC will provide investors significant color into the comp

    7/6/26 9:51:00 AM ET
    $TDAC

    TDAC Announces Very Successful Share Redemption Results in Connection with Extension Vote

    85% of Shares are not Redeemed, resulting in TDAC maintaining $156.8mm in trust95% of the Shares Voted Were In Favor of the ExtensionThese Great Results Follow the Momentum of the May 27, 2026 announcement of TDAC's Entry into a Merger Agreement with PrologiumPrologium is a global leader in next generation lithium ceramic battery technology, moving into growth markets, including AI Data Centers, aerospace, robotics, defense and electric vehiclesNEW YORK, June 22, 2026 /PRNewswire/ -- Translational Development Acquisition Company (NYSE:TDAC) (the "Company" or "TDAC") announced the very successful results of the shareholder vote held on 6/17/26 regarding the proposed extension of the SPAC life

    6/22/26 7:05:00 AM ET
    $TDAC

    ProLogium, a Next Generation Solid-State Battery Developer with 10+ Years of Proven Commercialization, to List on the Nasdaq through a Merger with Translational Development Acquisition Corp.

    ProLogium reached commercial-scale manufacturing for solid-state batteries in 2013, later delivered the world's first solid-state battery demo car with ENOVATE Motor in 2019. ProLogium has shipped a total of over 2.4 million battery cells to customers since 2013, of which more than 800,000 are its 3rd-generation batteries from the Gigafactory in Taiwan. With a portfolio of 1,100+ patents, ProLogium has introduced its 4th-generation superfluidized inorganic solid-state battery solution with zero thermal runaway, high energy density, low temperature performance, fast charging, competitive cost, and commercial readiness. Pre-money valuation of ProLogium is expected to be approximately $3.8 bill

    5/27/26 7:00:00 AM ET
    $TDAC

    $TDAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital Markets initiated coverage on Trident Acquisitions with a new price target

    Northland Capital Markets initiated coverage of Trident Acquisitions with a rating of Outperform and set a new price target of $16.00

    9/21/21 8:09:12 AM ET
    $TDAC

    $TDAC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Translational Development Acquisition Corp.

    SCHEDULE 13G/A - Translational Development Acquisition Corp. (0001926599) (Subject)

    7/16/26 1:38:54 PM ET
    $TDAC

    Translational Development Acquisition Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Translational Development Acquisition Corp. (0001926599) (Filer)

    7/8/26 8:05:31 AM ET
    $TDAC

    SEC Form DEFA14A filed by Translational Development Acquisition Corp.

    DEFA14A - Translational Development Acquisition Corp. (0001926599) (Filer)

    6/23/26 10:25:11 AM ET
    $TDAC

    $TDAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed

    SC 13G - Trident Acquisitions Corp. (0001673481) (Subject)

    2/12/21 4:30:21 PM ET
    $TDAC